Pharmaceutical Products: approximately 70% of revenue
Medical Devices: approximately 20% of revenue
Research and Development Services: approximately 10% of revenue

TOP 3 Markets:
China: approximately 60%
Southeast Asia: approximately 20%
Europe: approximately 10%

Haisco Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by medical devices and research and development services. The Chinese market is the dominant sales market, attributed to the strong local presence and demand for pharmaceutical products in China. Southeast Asia and Europe are also significant markets served through strategic expansion and partnerships.

Production Sites: Chengdu, China; Hangzhou, China

Haisco Pharmaceutical Group Co., Ltd. mainly produces its products in China, with significant production facilities in Chengdu and Hangzhou. These locations are strategically chosen to maximize production efficiency and optimize logistics within China.

In recent years, the company has invested in modernizing and expanding its production capacities to meet the increasing market demands and ensure the quality of its pharmaceutical products.

Focus on Research and Development: Increase in R&D budget by 20% (2024)

International Expansion: Entry into the European market (2024)

Product Diversification: Launch of three new medications (2025)

Haisco Pharmaceutical Group Co., Ltd. is focusing on increased investment in research and development to develop innovative medications and expand its product pipeline. This strategy aims to enhance competitiveness and explore new market opportunities.

Additionally, the company plans to expand its international presence, particularly by entering the European market. This will be supported by strategic partnerships and alliances with local companies.

Diversification of the product portfolio is another key focus, with Haisco planning to introduce several new medications to respond to changing needs in the healthcare sector and tap into new revenue sources.

Main raw materials: Active ingredients, excipients, packaging materials
Countries of origin: India, Germany, China (local sourcing)

Haisco Pharmaceutical Group Co., Ltd. mainly imports pharmaceutical active ingredients and excipients needed for the production of their products. India is a significant supplier of active ingredients due to its strong position in pharmaceutical production. Germany provides specialized excipients and technologies that are widely used in the pharmaceutical industry.

In addition, Haisco sources packaging materials from both domestic and international markets to ensure the quality and safety of their products. The exact distribution of imports may vary depending on production needs and market conditions.

Market share in China: 5% (estimated, 2025)
Research and development expenditure: 12% of revenue (2024)
Patents: Over 150 active patents (2025)

Haisco Pharmaceutical Group Co., Ltd. has established itself as a significant player in the Chinese pharmaceutical market. The company's competitive advantage is based on several factors, including a strong R&D focus that enables it to continuously develop innovative products. The share of R&D expenses in revenue is relatively high at 12%, indicating a strategic investment in future sustainability.

Furthermore, Haisco has an extensive portfolio of over 150 active patents that protect the company from imitators and increase market entry barriers for competitors. This strengthens Haisco's position in the market and allows the company to stand out from the competition.

Additionally, Haisco benefits from a solid market presence in China, with an estimated market share of 5%. This demonstrates the company's ability to effectively market and distribute its products, serving as another indicator of its competitive advantage.

Institutional Investor Share: Approximately 35% (estimated for 2025 based on trends from previous years)

Insider Purchases/Sales: No significant transactions reported in the last 12 months (as of 2025)

The institutional investor share in Haisco Pharmaceutical Group Co., Ltd. is estimated to be around 35%. This figure is based on trends from previous years, with institutional investors typically holding a significant stake in publicly traded companies in China.

Regarding insider purchases or sales, there have been no significant transactions in the past year. This could indicate that the management has confidence in the current company strategy or that no major changes in ownership structure are expected.

Market share of Haisco Pharmaceutical Group Co., Ltd.: 3.5% (estimated, 2025)

Top competitors and their market shares:

1. CSPC Pharmaceutical Group Limited: 8.2%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 7.5%
3. Sinopharm Group Co., Ltd.: 7.0%
4. China Resources Pharmaceutical Group Limited: 6.8%
5. Jiangsu Hengrui Medicine Co., Ltd.: 6.5%
6. Haisco Pharmaceutical Group Co., Ltd.: 3.5%
7. Tasly Pharmaceutical Group Co., Ltd.: 3.2%
8. Fosun Pharma: 3.0%
9. Yunnan Baiyao Group Co., Ltd.: 2.8%
10. Tong Ren Tang Technologies Co., Ltd.: 2.5%

Moat of Haisco Pharmaceutical Group Co., Ltd.:

Haisco Pharmaceutical Group Co., Ltd. has a moderate moat, mainly based on its specialization in specific pharmaceutical niche markets. The company has invested in research and development to create innovative products that offer some market differentiation.

Compared to larger competitors like CSPC Pharmaceutical and Shanghai Pharmaceuticals, which have more extensive distribution networks and a broader product range, Haisco's moat is less pronounced. These larger companies benefit from economies of scale and stronger brand presence, giving them a competitive advantage.

However, Haisco could strengthen its moat by further focusing on innovative therapies and strategic partnerships. Currently, the advantage remains limited compared to the industry's leading companies.

Revenue Growth: 10.5% (2024) Profit Growth: 8.9% (2024) Research and Development Ratio: 12% of revenue (2024)

Haisco Pharmaceutical Group Co., Ltd. achieved solid revenue growth of 10.5% in 2024, attributed to successful expansion into new markets and a strong product pipeline. The 8.9% profit growth demonstrates the company's ability to effectively manage costs and benefit from its investments.

The research and development ratio of 12% of revenue highlights the company's commitment to innovation and developing new products. This is a positive indicator of future growth potential, enabling Haisco to remain competitive and seize new market opportunities.

Overall, Haisco's financial performance and strategic direction suggest that the stock could be a promising investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (estimated for 2025)

Dividend History: Continuous payout over the last 5 years

Haisco Pharmaceutical Group Co., Ltd. has paid dividends in recent years and shows a dividend yield of approximately 2.5% for the year 2025. The company has regularly paid dividends over the past five years, indicating a certain reliability in its payouts.

The stability of dividend payments suggests that Haisco has a solid financial foundation and is committed to providing shareholders with continuous returns. The reliability of the payout is supported by the company's financial health and profitability.